Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes
Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II
Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…Non-pharmacological Treatment for Parkinson’s Disease Patients with Depression: A Meta-analysis of Repetitive Transcranial Magnetic Stimulation and Cognitive-Behavioral Treatment
Objective: This meta-analysis aims to assess the effect of non-pharmacological treatments for depression in patients with PD. Background: Antidepressants are the mainstay of treatment for…Novel walker attachment for gait dysfunction in Parkinson’s disease: Case report
Objective: To describe a patient with advanced PD who noted improved balance and fewer falls while using a novel belt attachment for his assistive device.…Ceftriaxone improves motor function in a rat hemi-parkinsonian model: Potential to delay bilateral progression of motor deficits in Parkinson’s disease
Objective: This study sought to evaluate the impact of ceftriaxone, as a potential repurposed drug, in ameliorating motor decline in a unilateral rat 6-hydroxydopamine (6-OHDA)…Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model
Objective: Today, the use of medicinal herbs to prevent and slow down the progression of Parkinson's disease has attracted the attention of researchers. The phenolic…Anticholinergic Burden in Parkinson’s Disease Patients in India – A Hospital Based Study
Objective: To determine the cumulative anticholinergic burden in Indian Parkinson’s disease (PD) patients and to correlate the same with cognitive impairment and gait disturbance. Background:…Effects of a next-generation neurotrophic compound in a toxin model of Parkinson’s disease
Objective: Investigate the effects of a peripherally administered novel neurotrophic compound, CMx01a, in 6-hydroxydopamine rat model of Parkinson’s disease. Background: Neurotrophic factors are promising drug…Brain 5-HT1 receptor binding in multiple system atrophy: A [18F]-MPPF PET study
Objective: The primary objective was to compare brain 5-HT1a receptor binding between patients with multiple system atrophy (MSA) and healthy controls (HC). The secondary objectives…Glucocerebrosidase activity and atypical parkinsonism: a multi-centre exploratory study
Objective: We aimed to determine the frequency of Glucocerebrosidase (GBA) deficiency (subclinical Gaucher's Disease type 1, GD1) in patients with atypical parkinsonism (AP) with features…
- « Previous Page
- 1
- …
- 98
- 99
- 100
- 101
- 102
- …
- 149
- Next Page »